Skip to main content
PMC home page
Frontiers in Aging Neuroscience logoLink to Frontiers in Aging Neuroscience
. 2022 Sep 30;14:1018610. doi: 10.3389/fnagi.2022.1018610

Evaluation of cannabinoid type 2 receptor expression and pyridine-based radiotracers in brains from a mouse model of Alzheimer’s disease

Vasil Kecheliev 1, Francesco Spinelli 2, Adrienne Herde 2, Ahmed Haider 2, Linjing Mu 2,3, Jan Klohs 4, Simon M Ametamey 2,*, Ruiqing Ni 1,4,*
PMCID: PMC9561934  PMID: 36248003

Abstract

Neuroinflammation plays an important role in the pathophysiology of Alzheimer’s disease. The cannabinoid type 2 receptor (CB2R) is an emerging target for neuroinflammation and therapeutics of Alzheimer’s disease. Here, we aim to assess the alterations in brain CB2R levels and evaluate novel CB2R imaging tracers in the arcAß mouse model of Alzheimer’s disease amyloidosis. Immunohistochemical staining for amyloid-ß deposits (6E10), microgliosis (anti-Iba1 and anti-CD68 antibodies), astrocytes (GFAP) and the anti-CB2R antibody was performed on brain slices from 17-month-old arcAß mice. Autoradiography using the CB2R imaging probes [18F]RoSMA-18-d6, [11C]RSR-056, and [11C]RS-028 and mRNA analysis were performed in brain tissue from arcAß and non-transgenic littermate (NTL) mice at 6, 17, and 24 months of age. Specific increased CB2R immunofluorescence intensities on the increased number of GFAP-positive astrocytes and Iba1-positive microglia were detected in the hippocampus and cortex of 17-month-old arcAß mice compared to NTL mice. CB2R immunofluorescence was higher in glial cells inside 6E10-positive amyloid-ß deposits than peri-plaque glial cells, which showed low background immunofluorescence in the hippocampus and cortex of 17-month-old arcAß mice. Ex vivo autoradiography showed that the specific binding of [18F]RoSMA-18-d6 and [11C]RSR-056 was comparable in arcAß and NTL mice at 6, 17, and 24 months of age. The level of Cnr2 mRNA expression in the brain was not significantly different between arcAß and NTL mice at 6, 17, or 24 months of age. In conclusion, we demonstrated pronounced specific increases in microglial and astroglial CB2R expression levels in a mouse model of AD-related cerebral amyloidosis, emphasizing CB2R as a suitable target for imaging neuroinflammation.

Keywords: Alzheimer’s disease, positron emission tomography, astrocyte, microglia, cannabinoid type 2 receptor (CB2R), neuroinflammation, autoradiography

Introduction

Abnormal accumulation of amyloid-beta (Aβ) aggregates in Alzheimer’s disease (AD) leads to a cascade of pathophysiological changes, including neuroinflammation, microvascular alterations, synaptic dysfunction, and neuronal loss. Neuroinflammation, including gliosis and increased levels of complements, cytokines, and chemokines, plays an important role in the development of AD (Rapic et al., 2013; Heneka et al., 2015; López et al., 2018; Xin et al., 2020). Microglia are resident macrophages in the central nervous system (CNS) that are important for maintaining brain homeostasis (Heneka et al., 2015) but have also been implicated in the pathophysiology of AD (Deczkowska et al., 2018; Kiani Shabestari et al., 2022). Increased numbers of astrocytes and microglia were observed in the vicinity of Aβ plaques in post-mortem AD mouse model brains and patients with AD (Heneka et al., 2015). Recent single-cell sequencing transcriptomics for disease-associated microglia (DAM) indicates the presence of transcriptionally distinct and neurodegeneration-specific microglial profiles with potential significance in AD signatures, including TREM2, CD33, and ApoE (Keren-Shaul et al., 2017; Deczkowska et al., 2018; Song and Colonna, 2018; Grubman et al., 2021).

Positron emission tomography (PET) ligands for detecting neuroinflammation microgliosis and astrocytosis in AD for understanding the disease mechanism. Early neuroinflammation has been reported in AD and in amyloidosis animal models (Rodriguez-Vieitez et al., 2015; Kreisl et al., 2020; Biechele et al., 2021; Ni et al., 2021b). Among these, PET ligands for translocator protein (TSPO) are the most widely used for detecting neuroinflammation. Previous TSPO PET imaging studies have shown microglial activation preceding Aβ deposition in several animal models, such as APP23, J20, APPSL70, AppNL–G–F, and PS2APP mice (Sacher et al., 2019; Biechele et al., 2021). However, limitations in the complex cellular locations, polymorphisms, and non-specific binding of TSPO and whether TSPO measures microglial proliferation or activation remain to be addressed (Leng and Edison, 2021; Zhou et al., 2021). Novel specific PET tracers for visualizing microgliosis, especially the DAM subtype, are highly desired.

Cannabinoid type 2 receptors (CB2Rs) are mainly expressed by immune cells, including monocytes and macrophages. In the CNS, CB2Rs are mainly expressed on microglia at low levels under physiological conditions and are upregulated in acute inflammatory conditions, such as ischemic stroke (Cristino et al., 2020). CB2Rs are essential to induce Toll-like receptor-mediated microglial activation (Reusch et al., 2022). Activation of CB2R offers neuroprotective effects, such as reducing Aβ-induced neuronal toxicity (Köfalvi et al., 2016; Navarro et al., 2018; Wang et al., 2018b; Scheiner et al., 2019; Zhao et al., 2020), suppressing microglial activation (Ehrhart et al., 2005; Ramírez et al., 2005), restoring cognitive capacity (Wu et al., 2017), and ameliorating novel object recognition in animal models of amyloidosis (Li et al., 2019). Thus, CB2R has been of therapeutic interest in AD (Köfalvi et al., 2016). However, the expression levels of CB2R in animal models of AD amyloidosis have not been extensively characterized. CB2R has been shown to be increased and involved in Aβ pathology in 5 × FAD (López et al., 2018; Zhang and Chen, 2018) and J20 mouse models of AD amyloidosis (Koppel et al., 2014) but reduced in the brains of 3 × Tg mice (with both Aβ and tau pathology) and in aging C57B6 mice (Wang et al., 2018a).

Several CB2R ligands have been developed and evaluated (Ni et al., 2019b), including [11C]NE40 (Vandeputte et al., 2012), [11C]A-836339 (MDTC) (Pottier et al., 2017; Du et al., 2022), [18F]MA3 (Attili et al., 2019), [18F]FC0324 (Caillé et al., 2017), [18F]JHU94620 (Moldovan et al., 2016), [18F]LU13 (Gündel et al., 2022), [18F]DM102 (Modemann et al., 2022), [18F]CRA13 (Hassan et al., 2020), [11C]RS-016 (Meletta et al., 2017), [11C]RS-028 (Haider et al., 2018), [11C]RSR-056 (Slavik et al., 2015), and [18F]RoSMA-18-d6 (Haider et al., 2020). Thus far, only one in-human in vivo CB2R PET using [11C]NE40 (Ahmad et al., 2016) in patients with AD and healthy controls has been reported, showing no group difference. Only the tracer [11C]A-836339 has been evaluated in an AD animal model: Increased [11C]A-836339 uptake was observed in the cortex, cerebellum and whole brain of J20 mice compared to wild-type mice (Savonenko et al., 2015); another [11C]A-836339 microPET study showed that the uptake was blockable in the cortex of APP/PS1 mice (Horti et al., 2010).

The aim of the current study was to assess the alterations in CB2R and distribution in the brain of the arcAß mouse model of AD amyloidosis and to evaluate the recently developed pyridine-derived CB2R tracers [11C]RS-028, [18F]RoSMA-18-d6, and [11C]RSR-056, which exhibit subnanomolar affinity and high selectivity toward CB2R (Ni et al., 2021a).

Materials and methods

Animals

Twenty transgenic arcAβ mice overexpressing the human APP695 transgene containing the Swedish (K670N/M671L) and Arctic (E693G) mutations under control of the prion protein promoter at 6, 17, and 24 months of age and 20 age-matched non-transgenic littermates (NTLs) of both sexes were used in this study (Knobloch et al., 2007; Merlini et al., 2011; Ni et al., 2022). The arcAβ mouse model exhibits parenchymal plaque as well as cerebral amyloid angiopathy and shows impaired cerebrovascular functions (Ni et al., 2018, 2019a). Paper tissue and red mouse house (Tecniplast®, Buguggiate VA, Italy) shelters were placed in cages for environmental enrichment. All experiments were performed in accordance with the Swiss Federal Act on Animal Protection and were approved by the Cantonal Veterinary Office Zurich ZH082/18.

For mRNA and autoradiography, arcAβ and age-matched NTL mice at 6, 17, and 24 months of age were anesthetized under 5% isoflurane and decapitated. One brain hemisphere from arcAß mice and NTLs was immediately frozen in liquid nitrogen and stored at −80°C as described earlier (Ni et al., 2021a). The other half of the brain hemisphere was embedded in Tissue Tekv (Sakura® Finetek, Torrance, CA, USA), frozen, and stored at −80°C for autoradiography. For immunofluorescence staining, mice were perfused under ketamine/xylazine/acepromazine maleate anesthesia (75/10/2 mg/kg body weight, i.p. bolus injection) with ice-cold 0.1 M phosphate-buffered saline (PBS, pH 7.4, Sigma Aldrich, Burlington, VT, USA) and 4% paraformaldehyde in 0.1 M PBS (pH 7.4), fixed for 2 h in 4% paraformaldehyde (pH 7.4), and then stored in 0.1 M PBS (pH 7.4) at 4°C.

mRNA isolation and real-time polymerase chain reaction

Total mRNA isolation of the brain tissue from arcAβ and age-matched NTL mice at 6, 17, and 24 months of age was performed according to the protocols of the Isol-RNA Lysis Reagent (5 Prime Sciences, Montreal, Canada) and the bead-milling TissueLyser system (Qiagen, Hilden, Germany) (Ni et al., 2021a). A QuantiTect® Reverse Transcription Kit (Qiagen) was used to generate cDNA. The primers (Microsynth, Balgach, Switzerland) used for quantitative polymerase chain reaction (qPCR) are summarized in Supplementary Table 1. Quantitation of Cnr2 mRNA expression was performed with the DyNAmo Flash SYBR® Green qPCR Kit (Thermo Fisher Scientific, Waltham, MA, USA) using a 7900 HT Fast Real-Time PCR System (Applied Biosystems, Waltham, MA, USA). The amplification signals were detected in real time, which permitted accurate quantification of the amounts of the initial RNA template over 40 cycles according to the manufacturer’s protocol. All reactions were performed in duplicate within three independent runs, and each reaction was normalized against the expression of beta-actin. Quantitative analysis was performed using SDS Software (v2.4) and a previously described 2–ΔΔCt quantification method (Livak and Schmittgen, 2001). The specificity of the PCR products of each run was determined and verified with SDS dissociation curve analysis.

Immunofluorescence

For immunohistochemical analysis, brain tissue from arcAβ and age-matched NTL mice at 17 months of age was used. Coronal brain sections (40 μm) were cut around Bregma 0 to −2 mm and stained with anti-Aβ antibody 6E10, anti-ionized calcium-binding adapter 1 (Iba1) and anti-CD68 for microgliosis, GFAP for astrocytes and anti-CB2R antibody as previously described (Kecheliev et al., 2022; Supplementary Table 2). The CB2R antibody used in this study targets amino acid region 300–350 on murine CB2R protein expressed by cells of hematopoietic origin. Sections were mounted with Prolong Diamond mounting media. Imaging occurred at ×20 magnification using an Axio Observer Z1 slide scanner (Zeiss, Oberkochen, Germany) using the same acquisition settings for all brain slices and at ×63 magnification using a Leica SP8 confocal microscope (Leica, Wetzlar, Germany). The images were analyzed by a person blinded to the genotype using QuPath and ImageJ (NIH, USA). The colocalization of CB2R with plaque (6E10 channel), GFAP+ astrocytes or Iba1+ microglia in the cortex and hippocampus was determined on ×63-magnification images. The amount of CB2R immunofluorescence within these masks was determined by measuring the mean CB2R intensity as well as its integrated density (factor of area and average intensity).

Radiosynthesis and autoradiography

[18F]RoSMA-18-d6 (affinity Ki = 0.8 nM, CB2R/CB1R > 12,000), [11C]RSR-056 and [11C]RS-028 were synthesized and purified as described previously (Slavik et al., 2015; Haider et al., 2018, 2020; Ni et al., 2021a) and formulated with 5% ethanol in water. The molar activities were 156–194, 52.3, and 86.7–178 GBq/μmol for [18F]RoSMA-18-d6, [11C]RSR-056, and [11C]RS-028, respectively. The radiochemical purity for all three radioligands was >99%. Autoradiography was performed as described previously (Haider et al., 2020). Dissected mouse brains were embedded in Tissue Tek, cut into 10 μm thick sagittal sections on a cryostat (Cryo-Star HM-560MV; Microm, Thermo Scientific, Waltham, MA, USA) and stored at −80°C. We first compared the percentage of specific binding of [18F]RoSMA-18-d6, [11C]RSR-056, and [11C]RS-028 using brain tissue slices from the same arcAβ mice at 17 months of age (n = 3). Next, brain tissue slices from the arcAβ and age-matched NTL mice at 6 months of age (n = 5, 6), 17 months of age (n = 4, 5), and 24 months of age (n = 5, 5) were used in [18F]RoSMA-18-d6 autoradiography. Brain tissue slices from the arcAβ and age-matched NTL mice at 6 months of age (n = 3, 3), 17 months of age (n = 3, 3), and 24 months of age (n = 3, 3) were used in [11C]RSR-056 autoradiography. Autoradiography binding data from the same mice was analyzed using correlation analysis.

For [18F]RoSMA-18-d6 and [11C]RSR-056 autoradiography, slices were thawed on ice and preconditioned in ice-cold buffer (pH 7.4) containing 50 mM TRIS Sigma Aldrich, Burlington, VT, USA, 5 mM MgCl2 Sigma Aldrich, Burlington, VT, USA, and 0.1% fatty acid-free bovine serum albumin (BSA, Sigma Aldrich, Burlington, VT, USA). The tissue slices were dried and then incubated with 1 ml of the corresponding radioligand (0.5 nM [18F]RoSMA-18-d6 and 2 nM [11C]RSR-056) for 15 min at room temperature in a humidified chamber. For blockade conditions, the selective CB2R antagonist GW405833 (10 μM, Sigma Aldrich, Burlington, VT, USA) was added to the solution containing the radioligand. A standard was place to calibrate the radioligand concentration for calculation of protein level. The slices were washed with ice-cold washing buffer (pH 7.4) containing 50 mM TRIS, 5 mM MgCl2, 0.1% fatty acid-free BSA, and ice-cold distilled water. For [11C]RS-028 autoradiography, slices were thawed on ice and preconditioned in ice-cold buffer (pH 7.4) containing 50 mM TRIS, 5 mM MgCl2, 2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma Aldrich, Burlington, VT, USA) and 0.1% fatty acid-free BSA. The tissue slices were dried and then incubated with 1 ml of the [11C]RS-028 (3 nM) for 15 min at room temperature in a humidified chamber. For blockade conditions, the selective CB2R antagonist GW405833 (10 μM) was added to the solution containing the radioligand. A standard was place to calibrate the radioligand concentration for calculation of protein level. Specific binding was calculated as the difference between total and blockade condition. After drying, the slices were exposed to a phosphorimager plate (FUJIFILM, Tokyo, Japan) for 30 min, and the film was scanned in a BAS5000 reader (FUJIFILM).

Statistics

Group comparisons in multiple brain regions were performed by using two-way ANOVA with Sidak’s post-hoc analysis (GraphPad Prism 9, GraphPad, San Diego, CA, USA). Comparisons for CB2R inside plaque, peri-plaque and parenchymal were performed by using one-way ANOVA with Tukey’s post-hoc analysis. All data are presented as the mean ± standard deviation. Significance was set at *p < 0.05.

Results

Increased cannabinoid type 2 receptor expression with proliferation of microglia and astrocytes in the brains of arcAβ compared to non-transgenic littermate

First, the regional CB2R level, the cellular source and the expression of CB2R (mean immunofluorescence on the area occupied by the selected marker) were assessed in the brains of arcAβ mice and NTL mice at 17 months of age. CB2R immunofluorescence intensity was increased approximately 4–10-fold in the cortex (4.45 ± 0.25 vs. 0.46 ± 0.25, p < 0.0001), hippocampus (4.82 ± 0.10 vs. 0.95 ± 0.27, p < 0.0001), and thalamus (1.87 ± 0.31 vs. 0.41 ± 0.05, p < 0.0001) of arcAß mice compared to NTL mice at 17 months of age (n = 3 per group) (Figures 1, 2A,B). The background signal of CB2R is low in the parenchyma (outside astrocytes/microglia) (Figures 1, 2H). CB2R signal density was calculated as the factor of average intensity and area of fluorescent image pixels.

FIGURE 1.

FIGURE 1

Open in a new tab

Increased cannabinoid type 2 receptor (CB2R) in microglia and astrocytes associated with amyloid-beta deposits in 17-month-old arcAβ mice. (A,B) Brain tissue sections of non-transgenic littermate (NTL, n = 3) and arcAβ mice (n = 3) were stained for Aβ (6E10 antibody, green), CB2R (cyan), and Iba1 (red) in the hippocampus (Hpc) and cortex (Ctx). Increased CB2R and Iba1 immunoreactivity inside and surrounding the plaque. (C,D) Staining for Aβ (6E10, green), CB2R (cyan), and GFAP (red) in the Hpc and Ctx. Nuclei were counterstained with DAPI (white). Increased CB2R and GFAP immunoreactivity inside and surrounding Aβ plaques. *Localization of CB2R on microglia or astrocytes outside plaque, #Colocalization of CB2R on microglia or astrocytes within plaque. Scale bar = 20 μm. CB2R immunoreactivity was detected on both microglia and astrocytes.

FIGURE 2.

FIGURE 2

Open in a new tab

Quantification of microgliosis-, astrocytosis-, cannabinoid type 2 receptor (CB2R), and Aβ plaque-associated enrichment in 17-month-old arcAβ mice. (A) Representative CB2R (red) and 6E10 (Aβ, green) staining in half hemisphere of one arcAβ mouse brain. White boxes in panel (A) indicate the regions including cortex (Ctx), cornu ammonus 1 (CA1) region of the hippocampus (Hpc) that zoomed-in in Figure 1. Scale bar = 1 mm. (B) Increased CB2R (% area) in the Ctx, Hpc, and thalamus (Thal) of arcAβ mice (n = 3) compared to non-transgenic littermates (NTLs, n = 3). (C,D) Increased levels of Iba1 (% area) in the Ctx, Hpc, and Thal and GFAP (% area) in the Ctx and Hpc of arcAβ mice (n = 3) compared to NTL (n = 3). (E,F) Increased CB2R signal density and mean signal intensity on both GFAP+ astrocytes and Iba1+ microglia of arcAβ mice (n = 3) compared to NTL (n = 3). (G) Increased 6E10 staining of Aβ plaque in the Ctx and Hpc of arcAβ mice (n = 3) compared to NTL (n = 3). (H) CB2R mean signal intensity on the glia inside plaque is higher than peri-plaque, with low background signal in the parenchymal of arcAβ mice. Data are presented as the mean ± standard deviation.

Colocalization analysis indicated that CB2R signal density was upregulated on both Iba1+ microglia (379855.49 ± 35254.48 vs. 6486.02 ± 2773.22, p < 0.0001) and GFAP+ astrocytes (250994.60 ± 31974.33 vs. 19568.63 ± 12282.96, p < 0.0001) in the brains of arcAß mice compared to NTL mice at 17 months of age (n = 3 per group) (Figure 2E). Furthermore, the average CB2R signal intensity is increased in image pixels indicating both Iba1+ microglia (55.25 ± 3.76 vs. 182.44 ± 11.10, p < 0.0001) and GFAP+ astrocytes (121.37 ± 11.80 vs. 7.02 ± 0.79, p < 0.0001) of arcAß mice compared to NTL mice at 17 months of age (n = 3 per group) (Figure 2F).

Increased cannabinoid type 2 receptor associated with 6E10-positive Aβ plaque in the brains of arcAβ compared to non-transgenic littermate

Increased 6E10 immunofluorescence intensity was observed in the cortex (3.48 ± 0.22 vs. 0.39 ± 0.15, p < 0.0001) and hippocampus (6.80 ± 0.77 vs. 0.42 ± 0.20, p < 0.0001) of arcAß mice compared to NTL mice at 17 months of age (n = 3 per group) and was comparable in the thalamus (0.95 ± 0.73 vs. 0.30 ± 0.20, p = 0.2936) (Figures 1, 2G). In the brains of arcAß mice at 17 months of age, CB2R immunofluorescence was located on microglia and astrocytes both inside/within plaques (Figure 1). The intra-plaque (98.27 ± 4.31 p < 0.0001) and peri-plaque (42.38 ± 9.84, p = 0.0007) glial CB2R levels were both 20-fold and 10-fold that in the parenchyma (4.5 ± 0.24) of the arcAβ mice (n = 3 per group), respectively. The glial-CB2R mean fluorescence intensity inside plaque was higher than that located peri-plaque of the arcAβ mice (p < 0.0001, n = 3 per group) (Figures 1, 2H).

Increased Iba1+ and CD68+ microglia and GFAP+ astrocytes in the brains of arcAβ mice compared to non-transgenic littermate mice

Next, the levels of activated microglia using Iba1 and CD68 and astrocytes using GFAP were assessed in the brains of arcAβ mice and NTL mice at 17 months of age (n = 3 per group). Increased numbers of microglia (Iba1% area) were observed in the vicinity of Aβ plaques and were upregulated in the cortex (3.99 ± 0.04 vs. 0.76 ± 0.68, p < 0.0001), hippocampus (4.44 ± 0.35 vs. 0.24 ± 0.33, p < 0.0001), and thalamus (3.81 ± 0.21 vs. 1.37 ± 0.80, p = 0.0001) of arcAβ mice at 17 months of age compared to NTL mice (n = 3 per group). Similarly, an increased GFAP% area was associated with plaque in the cortex (5.29 ± 1.57 vs. 0.56 ± 0.33, p < 0.0001) and hippocampus (5.75 ± 0.72 vs. 2.61 ± 0.53, p = 0.0021) of arcAβ mice at 17 months of age compared to NTL mice (n = 3 per group), but not in the thalamus (1.29 ± 0.87 vs. 0.70 ± 0.44, p = 0.7933) (Figures 1, 2C,D). CD68 is a lysosomal protein expressed at high levels by activated microglia and at low levels by resting microglia in the CNS. Reactive microglia indicated by increased CD68 surrounding amyloid plaques (6E10) were observed and increased in the cortex (2.74 ± 0.50 vs. 1.03 ± 0.29, p = 0.0003) of arcAβ mice at 17 months of age compared to NTL mice (n = 3 per group) and were comparable in the hippocampus (1.57 ± 0.40 vs. 0.82 ± 0.35, p = 0.0734) and thalamus (1.61 ± 0.19 vs. 1.10 ± 0.37, p = 0.2874) (Figure 3).

FIGURE 3.

FIGURE 3

Open in a new tab

Microgliosis in the 17-month-old arcAβ mouse brain. (A–C) Brain tissue sections of non-transgenic littermate (NTL, n = 3) and arcAβ mice (n = 3) were stained for 6E10 (green)/CD68 (red) in the hippocampus (Hpc) and cortex (Ctx). White boxes in panel (C) indicate the regions including cortex (Ctx), cornu ammonus 1 (CA1) region of the hippocampus (Hpc) that zoomed-in in panels (A,B). Nuclei were counterstained with DAPI (white). Scale bar = 20 μm (A,B), =1 mm (C). (D) Quantification of CD68 signals in the Hpc, Ctx, and thalamus (Thal) of arcAβ mice compared to NTL mice confirmed microgliosis in arcAβ mice.

No difference in whole-brain levels of [18F]RoSMA-18-d6 and [11C]RSR-056 specific binding or Cnr2 expression between arcAß and non-transgenic littermate mice of different ages

Autoradiography using [18F]RoSMA-18-d6 (0.5 nM), [11C]RSR-056 (2 nM), and [11C]RS-028 (3 nM) was performed on sagittal arcAß brain tissue at 17 months of age slides to assess the radioligand specificity. The concentrations of the radioligands used in autoradiography were determined based on previous publication (at half binding affinity of the ligand) [11C]RS-028 (Haider et al., 2018), [11C]RSR-056 (Slavik et al., 2015), and [18F]RoSMA-18-d6 (Haider et al., 2020)Ḟor the brain tissues, less than 50% of binding sites were blocked in the presence of CB2R antagonist GW405833 (10 μM). The percentage of specific binding is significantly lower than percentages previously reported for the spleen for these radioligands, likely due to the limited number of CB2R binding sites in the brain (Slavik et al., 2015; Haider et al., 2018, 2020). [18F]RoSMA-18-d6 (40.3 ± 9.2%) showed a higher percentage of specific binding than [11C]RSR-056 (32.0 ± 7.8%) and [11C]RS-028 (32.0 ± 12.8%, Supplementary Figure 1) on arcAß (n = 3) and NTL (n = 3) mouse brain tissue at 17 months of age 3.

Thus, [18F]RoSMA-18-d6 (0.5 nM) and [11C]RSR-056 (2 nM) were selected for further experiments to examine the CB2R levels in arcAß and NTL at 6, 17, and 24 months of age by autoradiography of mouse brain slices. As no specific regional pattern of [18F]RoSMA-18-d6 (at 0.5 nM) and [11C]RSR-056 (at 2 nM) specific binding was observed in arcAß and NTL mice at 6, 17, and 24 months of age, the specific binding level was analyzed using the whole hemisphere region-of-interest. No difference was observed in brain [18F]RoSMA-18-d6 (at 0.5 nM) levels between NTL and arcAß mice at 6 months of age (0.19 ± 0.03 vs. 0.18 ± 0.06 pmol/g tissue, n = 5, 6), 17 months of age (0.22 ± 0.01 vs. 0.19 ± 0.01 pmol/g tissue, n = 3, 5), and 24 months of age (0.20 ± 0.04 vs. 0.22 ± 0.06 pmol/g tissue, n = 5, 5) (Figures 4A,B). Similarly, for [11C]RSR-056 (2 nM), no difference in radioactivity accumulation was observed in the brains of NTL and arcAß mice at 6 months of age (0.11 ± 0.03 vs. 0.12 ± 0.02 pmol/g tissue, n = 5, 6), 17 months of age (0.18 ± 0.05 vs. 0.13 ± 0.02 pmol/g, n = 3, 5), and 24 months of age (0.14 ± 0.09 vs. 0.15 ± 0.03 pmol/g, n = 5, 5) (Figures 4C,D). There was a robust correlation between [11C]RSR-056 (2 nM) specific binding and [18F]RoSMA-18-d6 (at 0.5 nM) specific binding in arcAß and NTL mouse brains at 6, 17, and 24 months of age (Spearman rank, r = 0.8042, p = 0.0025) (Figure 4E).

FIGURE 4.

FIGURE 4

Open in a new tab

Comparable regional [18F]RoSMA-18-d6 and [11C]RSR-056 specific binding in the brains of arcAβ and non-transgenic mice at 6, 17, and 24 months of age. (A) Representative [18F]RoSMA-18-d6 (0.5 nM) autoradiographic images (total binding) of sagittal brain sections of arcAβ and non-transgenic littermate (NTL) mice at 6 months of age (n = 5, 6), 17 months of age (n = 4, 5), and 24 months of age (n = 5, 5). (C) Representative [11C]RSR-056 (2 nM) autoradiographic images (total binding) of sagittal brain sections of arcAβ and non-transgenic littermate (NTL) mice at 6 months of age (n = 3, 3), 17 months of age (n = 3, 3), and 24 months of age (n = 3, 3). (B,D) Quantification of specific binding of [18F]RoSMA-18-d6 (0.5 nM), and [11C]RSR-056 (2 nM) in the whole sagittal brain slice in panels (A,C). Two-way ANOVA, arcAβ vs. NTL. (E) Robust correlation between specific binding of [18F]RoSMA-18-d6 (0.5 nM) and [11C]RSR-056 (2 nM) autoradiograms on arcAβ and NTL mouse brain hemispheres (Spearman rank, r = 0.8042, p = 0.0025). (F) Cnr2 expression in arcAβ and NTL mouse brain hemisphere homogenates at 6 months of age (n = 5, 5), 17 months of age (n = 5, 6), and 24 months of age (n = 5, 5).

Next, the mRNA expression levels of Cnr2 were evaluated in the left hemisphere from the same cohort of arcAß and NTL mice in autoradiography at 6, 17, and 24 months of age that were assessed by [18F]RoSMA-18-d6 and [11C]RSR-056 autoradiography (n = 5–6/age group). No significant difference was observed in Cnr2 mRNA expression between the NTL and arcAß mice at 6 months of age (1.92 ± 1.72 vs. 1.83 ± 0.79), 17 months of age (4.65 ± 6.30 vs. 4.20 ± 4.43), and 24 months of age (1.33 ± 0.92 vs. 3.36 ± 3.07) (Figure 4F).

Discussion

Here, we demonstrated an increase in local CB2R expression levels in arcAβ mice at 17 months of age compared to NTL mice and evaluated novel PET tracers [11C]RSR-056 and [18F]RoSMA-18-d6 for detecting brain CB2R changes in arcAβ mice at 6, 17, and 24 months of age. Increased CB2R fluorescence intensities and numbers of microglia and astrocytes inside/surrounding Aß plaques were observed in arcAß mice compared to NTL mice at 17 months of age. However, no significant difference in CB2R levels was observed at the whole-brain level measured either by using autoradiography or by mRNA analysis in arcAβ compared to NTL mice at 6, 17, and 24 months of age.

Cannabinoid type 2 receptor has been an emerging target for imaging neuroinflammation partly due to its low expression levels under physiological conditions and upregulation under acute inflammatory conditions (Stella, 2010). The CB2R fluorescence intensity was greatly increased in arcAβ mice compared to NTL mice and was higher inside plaque than peri-plaque and in the parenchyma of arcAβ mice. This observation is different from a previous publication of a significant increase in CB2R intensities compared to the core of plaques (radius ≤7 μm) (Savonenko et al., 2015). In addition, recent studies have reported the astroglial and neuronal expression of CB2R in mouse and rat brains in addition to its expression on microglia by using immunostaining and RNAscope techniques (Van Sickle et al., 2005; Gong et al., 2006; Zarruk et al., 2012; Li and Kim, 2015; Savonenko et al., 2015; Yamagishi et al., 2019; Galán-Ganga et al., 2021). Savonenko et al. (2015) reported expression of CB2R in neurons; and astrocytes in the brain from J20 amyloidosis mouse model at 12 months of age, in additional to its microglial expression. In our results from the immunofluorescence staining, CB2R expression on both astrocytes and microglia was increased significantly in arcAβ mice compared to the negligible level in NTL mice at 17 months of age (Figures 1, 2). Concerns have been raised regarding the specificity of CB2R antibodies used in immunohistochemical staining. Specific neuronal subpopulations of CB2R have been shown by using fluorescence in situ hybridization and proximity ligand assays in non-human primates (Sierra et al., 2015). However, previous study has reported that CB2-GFP expression is colocalized with Iba1 staining of microglia but not with NeuN staining of neuron or GFAP staining of astrocyte in CB2-GFP BAC transgenic mice (Lundt et al., 2015). López et al. (2018) reported that CB2R-dependent-enhanced green fluorescent protein (EGFP) expression is limited to plaque-associated microglial cells but is absent in neurons and astrocytes in CB2EGFP/f/f/5 × FAD mice.

Although Cnr2 expression in AD APP/PS1 has been reported to be upregulated, great variation between animals and a low fold increase lead to insignificance in comparison (Aso et al., 2013; Vidal-Palencia et al., 2022). Recent gene expression analysis showed that regional Cnr2 expression differs between male/female APP/PS1 mice (Vidal-Palencia et al., 2022). Here, Cnr2 expression was analyzed using homogenates of half hemispheres of arcAβ and NTL mice with further dissection. No difference in Cnr2 expression between arcAβ and NTL mice of different ages was observed.

For preclinical imaging, high variabilities in imaging of brain CB2R levels among animal models of neuroinflammation were reported from previous studies. Upregulated levels of brain CB2R have been demonstrated in transient middle cerebral artery occlusion ischemic stroke mice using [18F]RoSMA-18-d6 (Ni et al., 2021a) and in senescence-accelerated SAMP10 mice using [11C]NE40 (Yamagishi et al., 2019). Another study by PET using [11C]A-836339 in a lipopolysaccharide-injected rat model did not report changes in tracer uptake following neuroinflammation (Pottier et al., 2017). MicroPET using [11C] A-836339 showed increased uptake in the brain areas with Aβ depositions in a J20 mouse model of AD (Ni et al., 2019b). In the only reported study in patients with AD using PET, Ahmad et al. (2016) reported lower CB2R availability in Aβ-positive AD patients than in healthy controls assessed by PET using [11C]NE40 and [11C]PIB, respectively. No relationship between [11C]NE40 and cerebral Aβ load was observed in this study.

[11C]RSR-056 and [18F]RoSMA-18-d6 showed 32 and 40% specific binding in the AD mouse brain, respectively, and there was no difference between arcAβ and NTL mice. One of the difficulties is the low CB2R expression level in the brain and the low number of binding sites. Using the same tracers, [11C]RS-028 (Haider et al., 2018), [11C]RSR-056 (Slavik et al., 2015), and [18F]RoSMA-18-d6 (Haider et al., 2020), lower non-specific binding has been shown in post-mortem spleen and spinal cord tissues from patients with amyotrophic lateral sclerosis than in those from healthy controls. Further development of CB2R tracers of even higher affinity to overcome the low number of binding sites (Bmax) is desired. In addition, as species differences exist regarding CB2R brain expression, further studies on post-mortem brain tissues from patients with AD will provide information on CB2R disease relevance.

There are several limitations in this study: (1) Negative control: CB2R has been considered difficult to validate by using immunohistochemical staining. Further studies using CB2R knockout mice showing absence of staining and binding of radioligand will be confirmative. (2) Sample size: Number of animals included in the mRNA and autoradiography experiment of this brief report is low. Further study using larger sample size will improve the accuracy of the results. (3) In vivo imaging: Autoradiography provides information on the probe binding specificity and identifies potential regions of interest with validation from immunohistochemical characterization. Due to a lack of difference from autoradiography, in vivo measurement has not been performed in the AD mouse models using the radioligands investigated.

Conclusion

In conclusion, increases in CB2R immunofluorescence intensity on the glia were detected in the brains of arcAβ mice compared to NTL mice and were associated with Aβ deposits. Further improvement of the binding properties of CB2R PET tracers will be needed to detect subtle changes in CB2R in an AD animal model.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Ethics statement

The animal study was reviewed and approved by the Cantonal Veterinary Office Zurich.

Author contributions

RN, JK, SA, and AHa designed the study. VK performed the staining and microscopy. LM synthesized the radioligands. FS performed the mRNA analysis. RN performed the autoradiography. VK, FS, LM, and RN performed data analysis. VK and RN wrote the initial manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors acknowledge Roger Schibli, Department of Chemistry and Applied Biosciences, ETH Zurich; Marie Rouault at the Institute for Biomedical Engineering, ETH Zurich; and Daniel Schuppli at the Institute for Regenerative Medicine, University of Zurich for technical assistance. The authors thank the ALS foundation for partially funding this project.

Funding

JK received funding from the Swiss National Science Foundation (320030_179277) in the framework of ERA-NET NEURON (32NE30_173678/1), the Synapsis Foundation. SA received funding from the ALS Foundation (1-005891-000). RN received funding from Vontobel Stiftung, University of Zurich [MEDEF-20-21]. Open access funding provided by ETH Zurich.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnagi.2022.1018610/full#supplementary-material

Click here for additional data file. (2.7MB, docx)

References

  1. Ahmad R., Postnov A., Bormans G., Versijpt J., Vandenbulcke M., Van Laere K. (2016). Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease. Eur. J. Nucl. Med. Mol. Imaging 43 2219–2227. 10.1007/s00259-016-3457-7 [DOI] [PubMed] [Google Scholar]
  2. Aso E., Juvés S., Maldonado R., Ferrer I. (2013). CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers Dis. 35 847–858. 10.3233/jad-130137 [DOI] [PubMed] [Google Scholar]
  3. Attili B., Celen S., Ahamed M., Koole M., Haute C. V. D., Vanduffel W., et al. (2019). Preclinical evaluation of [18F]MA3: A CB2 receptor agonist radiotracer for PET. Br. J. Pharmacol. 176 1481–1491. 10.1111/bph.14564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Biechele G., Wind K., Blume T., Sacher C., Beyer L., Eckenweber F., et al. (2021). Microglial activation in the right amygdala-entorhinal-hippocampal complex is associated with preserved spatial learning in App(NL-G-F) mice. Neuroimage 230:117707. 10.1016/j.neuroimage.2020.117707 [DOI] [PubMed] [Google Scholar]
  5. Caillé F., Cacheux F., Peyronneau M. A., Jego B., Jaumain E., Pottier G., et al. (2017). From Structure-Activity relationships on thiazole derivatives to the in vivo evaluation of a new radiotracer for cannabinoid subtype 2 PET imaging. Mol. Pharm. 14 4064–4078. 10.1021/acs.molpharmaceut.7b00746 [DOI] [PubMed] [Google Scholar]
  6. Cristino L., Bisogno T., Di Marzo V. (2020). Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 16 9–29. 10.1038/s41582-019-0284-z [DOI] [PubMed] [Google Scholar]
  7. Deczkowska A., Keren-Shaul H., Weiner A., Colonna M., Schwartz M., Amit I. (2018). Disease-Associated microglia: A universal immune sensor of neurodegeneration. Cell 173 1073–1081. 10.1016/j.cell.2018.05.003 [DOI] [PubMed] [Google Scholar]
  8. Du Y., Coughlin J., Brosnan M. K., Chen A., Shinehouse L., Abdallah R., et al. (2022). PET imaging of the cannabinoid receptor type 2 in humans using [11C]MDTC. Res. Sq. 10.21203/rs.3.rs-1479303/v1 [DOI] [PubMed] [Google Scholar]
  9. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., et al. (2005). Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2:29. 10.1186/1742-2094-2-29 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Galán-Ganga M., Rodríguez-Cueto C., Merchán-Rubira J., Hernández F., Ávila J., Posada-Ayala M., et al. (2021). Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Acta Neuropathol. Commun. 9:90. 10.1186/s40478-021-01196-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gong J. P., Onaivi E. S., Ishiguro H., Liu Q. R., Tagliaferro P. A., Brusco A., et al. (2006). Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res. 1071 10–23. 10.1016/j.brainres.2005.11.035 [DOI] [PubMed] [Google Scholar]
  12. Grubman A., Choo X. Y., Chew G., Ouyang J. F., Sun G., Croft N. P., et al. (2021). Transcriptional signature in microglia associated with Aβ plaque phagocytosis. Nat. Commun. 12:3015. 10.1038/s41467-021-23111-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gündel D., Deuther-Conrad W., Ueberham L., Kaur S., Otikova E., Teodoro R., et al. (2022). Structure-based design, optimization, and development of [(18)F]LU13: A novel radioligand for cannabinoid receptor type 2 imaging in the brain with PET. J. Med. Chem. 65 9034–9049. 10.1021/acs.jmedchem.2c00256 [DOI] [PubMed] [Google Scholar]
  14. Haider A., Gobbi L., Kretz J., Ullmer C., Brink A., Honer M., et al. (2020). Identification and preclinical development of a 2,5,6-trisubstituted fluorinated pyridine derivative as a radioligand for the positron emission tomography imaging of cannabinoid type 2 receptors. J. Med. Chem. 63 10287–10306. 10.1021/acs.jmedchem.0c00778 [DOI] [PubMed] [Google Scholar]
  15. Haider A., Spinelli F., Herde A. M., Mu B., Keller C., Margelisch M., et al. (2018). Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea Huntington mouse model and human ALS spinal cord tissue. Eur. J. Med. Chem. 145 746–759. 10.1016/j.ejmech.2017.12.097 [DOI] [PubMed] [Google Scholar]
  16. Hassan A. H. E., Park K. T., Kim H. J., Lee H. J., Kwon Y. H., Hwang J. Y., et al. (2020). Fluorinated CRA13 analogues: Synthesis, in vitro evaluation, radiosynthesis, in silico and in vivo PET study. Bioorg. Chem. 99:103834. 10.1016/j.bioorg.2020.103834 [DOI] [PubMed] [Google Scholar]
  17. Heneka M. T., Carson M. J., El Khoury J., Landreth G. E., Brosseron F., Feinstein D. L., et al. (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 14 388–405. 10.1016/s1474-4422(15)70016-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Horti A. G., Gao Y., Ravert H. T., Finley P., Valentine H., Wong D. F., et al. (2010). Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg. Med. Chem. 18 5202–5207. 10.1016/j.bmc.2010.05.058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kecheliev V., Boss L., Maheshwari U., Konietzko U., Keller A., Razansky D., et al. (2022). Aquaporin 4 is differentially increased and depolarized in association with tau and amyloid-beta. bioRxiv [Preprint]. bioRxiv:2022.2004.2026.489273. 10.1101/2022.04.26.489273 [DOI] [PubMed] [Google Scholar]
  20. Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T. K., et al. (2017). A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 169 1276–1290.e17. 10.1016/j.cell.2017.05.018 [DOI] [PubMed] [Google Scholar]
  21. Kiani Shabestari S., Morabito S., Danhash E. P., McQuade A., Sanchez J. R., Miyoshi E., et al. (2022). Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice. Cell Rep. 39:110961. 10.1016/j.celrep.2022.110961 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Knobloch M., Farinelli M., Konietzko U., Nitsch R. M., Mansuy I. M. (2007). Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J. Neurosci. 27 7648–7653. 10.1523/jneurosci.0395-07.2007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Koppel J., Vingtdeux V., Marambaud P., D’Abramo C., Jimenez H., Stauber M., et al. (2014). CB2 Receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease. Mol. Med. 20 29–36. 10.2119/molmed.2013.00140.revised [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Kreisl W. C., Kim M. J., Coughlin J. M., Henter I. D., Owen D. R., Innis R. B. (2020). PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 19 940–950. 10.1016/s1474-4422(20)30346-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Köfalvi A., Lemos C., Martín-Moreno A. M., Pinheiro B. S., García-García L., Pozo M. A., et al. (2016). Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer’s disease. Neuropharmacology 110 519–529. 10.1016/j.neuropharm.2016.03.015 [DOI] [PubMed] [Google Scholar]
  26. Leng F., Edison P. (2021). Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here? Nat. Rev. Neurol. 17 157–172. 10.1038/s41582-020-00435-y [DOI] [PubMed] [Google Scholar]
  27. Li C., Shi J., Wang B., Li J., Jia H. (2019). CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP/PS1 mice. Neurosci. Lett. 707:134286. 10.1016/j.neulet.2019.134286 [DOI] [PubMed] [Google Scholar]
  28. Li Y., Kim J. (2015). Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience 311 253–267. 10.1016/j.neuroscience.2015.10.041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Livak K. J., Schmittgen T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25 402–408. 10.1006/meth.2001.1262 [DOI] [PubMed] [Google Scholar]
  30. Lundt R., Gennequin B., Schmoele A., Beins E., Schrage H., Krämer A., et al. (2015). Expression analysis of CB2-GFP BAC transgenic mice. PLoS One 10:e0138986. 10.1371/journal.pone.0138986 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. López A., Aparicio N., Pazos M. R., Grande M. T., Barreda-Manso M. A., Benito-Cuesta I., et al. (2018). Cannabinoid CB(2) receptors in the mouse brain: Relevance for Alzheimer’s disease. J. Neuroinflammation 15:158. 10.1186/s12974-018-1174-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Meletta R., Slavik R., Mu L., Rancic Z., Borel N., Schibli R., et al. (2017). Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [(11)C]RS-016 targeting CB2 in atherosclerosis. Nucl. Med. Biol. 47 31–43. 10.1016/j.nucmedbio.2017.01.001 [DOI] [PubMed] [Google Scholar]
  33. Merlini M., Meyer E. P., Ulmann-Schuler A., Nitsch R. M. (2011). Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice. Acta Neuropathol. 122 293–311. 10.1007/s00401-011-0834-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Modemann D. J., Mahardhika A. B., Yamoune S., Kreyenschmidt A. K., Maaß F., Kremers S., et al. (2022). Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging. Eur. J. Med. Chem. 232:114138. 10.1016/j.ejmech.2022.114138 [DOI] [PubMed] [Google Scholar]
  35. Moldovan R. P., Teodoro R., Gao Y., Deuther-Conrad W., Kranz M., Wang Y., et al. (2016). Development of a high-affinity PET radioligand for imaging cannabinoid subtype 2 receptor. J. Med. Chem. 59 7840–7855. 10.1021/acs.jmedchem.6b00554 [DOI] [PubMed] [Google Scholar]
  36. Navarro G., Borroto-Escuela D., Angelats E., Etayo Í, Reyes-Resina I., Pulido-Salgado M., et al. (2018). Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB(1) and CB(2) receptors and relevance for Alzheimer’s disease and levodopa-induced dyskinesia. Brain Behav. Immun. 67 139–151. 10.1016/j.bbi.2017.08.015 [DOI] [PubMed] [Google Scholar]
  37. Ni R., Chen Z., Deán-Ben X. L., Voigt F. F., Kirschenbaum D., Shi G., et al. (2022). Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice. Nat. Biomed. Eng. 10.1038/s41551-022-00906-1 [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  38. Ni R., Mu L., Ametamey S. (2019b). Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system. Acta Pharmacol. Sin. 40 351–357. 10.1038/s41401-018-0035-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ni R., Kindler D. R., Waag R., Rouault M., Ravikumar P., Nitsch R., et al. (2019a). fMRI reveals mitigation of cerebrovascular dysfunction by Bradykinin receptors 1 and 2 inhibitor noscapine in a mouse model of cerebral amyloidosis. Front. Aging Neurosci. 11:27. 10.3389/fnagi.2019.00027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Ni R., Rudin M., Klohs J. (2018). Cortical hypoperfusion and reduced cerebral metabolic rate of oxygen in the arcAβ mouse model of Alzheimer’s disease. Photoacoustics 10 38–47. 10.1016/j.pacs.2018.04.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Ni R., Röjdner J., Voytenko L., Dyrks T., Thiele A., Marutle A., et al. (2021b). In vitro characterization of the regional binding distribution of amyloid pet tracer florbetaben and the glia tracers deprenyl and PK11195 in autopsy Alzheimer’s brain tissue. J. Alzheimers Dis. 80 1723–1737. 10.3233/jad-201344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ni R., Müller Herde A., Haider A., Keller C., Louloudis G., Vaas M., et al. (2021a). In vivo imaging of cannabinoid type 2 receptors: Functional and structural alterations in mouse model of cerebral ischemia by PET and MRI. Mol. Imaging Biol. 10.1007/s11307-021-01655-4 [Epub ahead of print]. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Pottier G., Gómez-Vallejo V., Padro D., Boisgard R., Dollé F., Llop J., et al. (2017). PET imaging of cannabinoid type 2 receptors with [(11)C]A-836339 did not evidence changes following neuroinflammation in rats. J. Cereb. Blood Flow Metab. 37 1163–1178. 10.1177/0271678x16685105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Ramírez B. G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M. L. (2005). Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J. Neurosci. 25 1904–1913. 10.1523/jneurosci.4540-04.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Rapic S., Backes H., Viel T., Kummer M. P., Monfared P., Neumaier B., et al. (2013). Imaging microglial activation and glucose consumption in a mouse model of Alzheimer’s disease. Neurobiol. Aging 34 351–354. 10.1016/j.neurobiolaging.2012.04.016 [DOI] [PubMed] [Google Scholar]
  46. Reusch N., Ravichandran K. A., Olabiyi B. F., Komorowska-Müller J. A., Hansen J. N., Ulas T., et al. (2022). Cannabinoid receptor 2 is necessary to induce toll-like receptor-mediated microglial activation. Glia 70 71–88. 10.1002/glia.24089 [DOI] [PubMed] [Google Scholar]
  47. Rodriguez-Vieitez E., Ni R., Gulyás B., Tóth M., Häggkvist J., Halldin C., et al. (2015). Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: A correlative positron emission tomography and in vitro imaging study. Eur. J. Nucl. Med. Mol. Imaging 42 1119–1132. 10.1007/s00259-015-3047-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Sacher C., Blume T., Beyer L., Peters F., Eckenweber F., Sgobio C., et al. (2019). Longitudinal PET monitoring of amyloidosis and microglial activation in a second-generation amyloid-β mouse model. J. Nucl. Med. 60 1787–1793. 10.2967/jnumed.119.227322 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Savonenko A. V., Melnikova T., Wang Y., Ravert H., Gao Y., Koppel J., et al. (2015). Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: Immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One 10:e0129618. 10.1371/journal.pone.0129618 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Scheiner M., Dolles D., Gunesch S., Hoffmann M., Nabissi M., Marinelli O., et al. (2019). Dual-acting cholinesterase-human cannabinoid receptor 2 ligands show pronounced neuroprotection in vitro and overadditive and disease-modifying neuroprotective effects in vivo. J. Med. Chem. 62 9078–9102. 10.1021/acs.jmedchem.9b00623 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Sierra S., Luquin N., Rico A. J., Gómez-Bautista V., Roda E., Dopeso-Reyes I. G., et al. (2015). Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: Changes following experimental Parkinsonism. Brain Struct. Funct. 220 2721–2738. 10.1007/s00429-014-0823-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Slavik R., Grether U., Müller Herde A., Gobbi L., Fingerle J., Ullmer C., et al. (2015). Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor. J. Med. Chem. 58 4266–4277. 10.1021/acs.jmedchem.5b00283 [DOI] [PubMed] [Google Scholar]
  53. Song W. M., Colonna M. (2018). The identity and function of microglia in neurodegeneration. Nat. Immunol. 19 1048–1058. 10.1038/s41590-018-0212-1 [DOI] [PubMed] [Google Scholar]
  54. Stella N. (2010). Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58 1017–1030. 10.1002/glia.20983 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Van Sickle M. D., Duncan M., Kingsley P. J., Mouihate A., Urbani P., Mackie K., et al. (2005). Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310 329–332. 10.1126/science.1115740 [DOI] [PubMed] [Google Scholar]
  56. Vandeputte C., Casteels C., Struys T., Koole M., van Veghel D., Evens N., et al. (2012). Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model. Eur. J. Nucl. Med. Mol. Imaging 39 1796–1806. 10.1007/s00259-012-2209-6 [DOI] [PubMed] [Google Scholar]
  57. Vidal-Palencia L., Ramon-Duaso C., González-Parra J. A., Busquets-Garcia A. (2022). Gene expression analysis of the endocannabinoid system in presymptomatic APP/PS1 mice. Front. Pharmacol. 13:864591. 10.3389/fphar.2022.864591 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Wang L., Shi F. X., Xu W. Q., Cao Y., Li N., Li M., et al. (2018b). The down-expression of ACE and IDE exacerbates exogenous amyloid-β neurotoxicity in CB2R-/- Mice. J. Alzheimers Dis. 64 957–971. 10.3233/jad-180142 [DOI] [PubMed] [Google Scholar]
  59. Wang L., Liu B. J., Cao Y., Xu W. Q., Sun D. S., Li M. Z., et al. (2018a). Deletion of type-2 cannabinoid receptor induces Alzheimer’s disease-like Tau pathology and memory impairment through AMPK/GSK3β Pathway. Mol. Neurobiol. 55 4731–4744. 10.1007/s12035-017-0676-2 [DOI] [PubMed] [Google Scholar]
  60. Wu J., Hocevar M., Foss J. F., Bie B., Naguib M. (2017). Activation of CB(2) receptor system restores cognitive capacity and hippocampal Sox2 expression in a transgenic mouse model of Alzheimer’s disease. Eur. J. Pharmacol. 811 12–20. 10.1016/j.ejphar.2017.05.044 [DOI] [PubMed] [Google Scholar]
  61. Xin Q., Xu F., Taylor D. H., Zhao J. F., Wu J. (2020). The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders. Acta Pharmacol. Sin. 41 1507–1518. 10.1038/s41401-020-00530-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Yamagishi S., Iga Y., Nakamura M., Takizawa C., Fukumoto D., Kakiuchi T., et al. (2019). Upregulation of cannabinoid receptor type 2, but not TSPO, in senescence-accelerated neuroinflammation in mice: A positron emission tomography study. J. Neuroinflammation 16:208. 10.1186/s12974-019-1604-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Zarruk J. G., Fernández-López D., García-Yébenes I., García-Gutiérrez M. S., Vivancos J., Nombela F., et al. (2012). Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 43 211–219. 10.1161/strokeaha.111.631044 [DOI] [PubMed] [Google Scholar]
  64. Zhang J., Chen C. (2018). Alleviation of neuropathology by inhibition of monoacylglycerol lipase in APP transgenic mice lacking CB2 receptors. Mol. Neurobiol. 55 4802–4810. 10.1007/s12035-017-0689-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Zhao J., Wang M., Liu W., Ma Z., Wu J. (2020). Activation of cannabinoid receptor 2 protects rat hippocampal neurons against Aβ-induced neuronal toxicity. Neurosci. Lett. 735:135207. 10.1016/j.neulet.2020.135207 [DOI] [PubMed] [Google Scholar]
  66. Zhou R., Ji B., Kong Y., Qin L., Ren W., Guan Y., et al. (2021). PET imaging of neuroinflammation in Alzheimer’s disease. Front. Immunol. 12:3750. 10.3389/fimmu.2021.739130 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (2.7MB, docx)

Data Availability Statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary material.

Articles from Frontiers in Aging Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES